25,547 Shares in Novartis AG (NYSE:NVS) Acquired by Oxbow Advisors LLC

Oxbow Advisors LLC purchased a new stake in Novartis AG (NYSE:NVS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 25,547 shares of the company’s stock, valued at approximately $2,720,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Private Ocean LLC acquired a new position in shares of Novartis during the 1st quarter valued at $25,000. Frazier Financial Advisors LLC bought a new position in shares of Novartis during the 4th quarter worth about $26,000. Richardson Financial Services Inc. acquired a new stake in shares of Novartis in the 4th quarter valued at about $26,000. Clearstead Trust LLC increased its position in Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock valued at $26,000 after buying an additional 114 shares in the last quarter. Finally, New Millennium Group LLC acquired a new position in Novartis during the 2nd quarter worth approximately $28,000. 13.12% of the stock is currently owned by institutional investors.

Novartis Stock Up 0.1 %

NYSE:NVS traded up $0.16 during trading hours on Friday, hitting $116.65. 1,151,373 shares of the company traded hands, compared to its average volume of 1,407,379. Novartis AG has a one year low of $92.19 and a one year high of $120.92. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. The company has a market cap of $238.43 billion, a PE ratio of 15.75, a PEG ratio of 1.77 and a beta of 0.57. The firm’s 50-day simple moving average is $112.66 and its 200-day simple moving average is $104.51.

Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, July 18th. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.10. The business had revenue of $12.87 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same period in the previous year, the company earned $1.83 earnings per share. Equities analysts predict that Novartis AG will post 7.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on NVS shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $121.00 price objective (up previously from $119.00) on shares of Novartis in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Barclays upgraded shares of Novartis to a “strong sell” rating in a report on Monday, June 24th. Finally, Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novartis has an average rating of “Hold” and an average target price of $118.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.